Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.

[1]  Ahmed Kamel,et al.  Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Shujiro Okuda,et al.  Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine , 2016, Genome Medicine.

[3]  G. Botti,et al.  Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma , 2016, Oncotarget.

[4]  V. Torri,et al.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[5]  R. Labianca,et al.  Assessment of a HER2 scoring system for colorectal cancer: results from a validation study , 2015, Modern Pathology.

[6]  Ron Bose,et al.  HER2 activating mutations are targets for colorectal cancer treatment. , 2015, Cancer discovery.

[7]  B. Heppner,et al.  HER2/neu testing in primary colorectal carcinoma , 2014, British Journal of Cancer.

[8]  L. Mazzucchelli,et al.  HER2 in solid tumors: more than 10 years under the microscope; where are we now? , 2014, Future oncology.

[9]  Aimin Li,et al.  Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. , 2014, International journal of clinical and experimental pathology.

[10]  H. Lee,et al.  HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression , 2014, PloS one.

[11]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[12]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jeffrey J Meyer,et al.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .

[14]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[15]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[16]  M. Odenthal,et al.  β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis , 2011, International Journal of Colorectal Disease.

[17]  A. Ardizzoni,et al.  Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma , 2011, British Journal of Cancer.

[18]  S. Chandarlapaty,et al.  HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies , 2011, Expert review of anticancer therapy.

[19]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[20]  M. Zampino,et al.  Rectal cancer. , 2009, Critical reviews in oncology/hematology.

[21]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[22]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Osamura,et al.  Assessment of a New Anti-HER2 Monoclonal Antibody, SV2-61γ: A Best Concordance With HER2 FISH , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[24]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  G. Sauter,et al.  Close association between HER-2 amplification and overexpression in human tumors of non-breast origin , 2007, Modern Pathology.

[26]  G. Sauter,et al.  HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer , 2006, Journal of Clinical Pathology.

[27]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[28]  Xiaoling Li,et al.  Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study , 2004, Modern Pathology.

[29]  K. Pavelić,et al.  The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. , 1997, Gastroenterology.

[30]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[31]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[32]  M. Kraus,et al.  Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. , 1989, Genomics.

[33]  A. Reyners,et al.  A 21-year-old patient with a HER2-positive colorectal cancer. , 2015, Gastroenterology.

[34]  Mitch Dowsett,et al.  HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity , 2014, Modern Pathology.

[35]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[36]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[37]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[38]  P. Beuzeboc,et al.  Targeting HER2 in other tumor types. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  M. Bui,et al.  Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. , 2000, Annals of clinical and laboratory science.